109 related articles for article (PubMed ID: 10517361)
1. Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum.
Allen GD; Brookes ST; Barrow A; Dunn JA; Grosse CM
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):383-93. PubMed ID: 10517361
[TBL] [Abstract][Full Text] [Related]
2. Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor (GG167) in human serum by pre-column fluorescence derivatisation using benzoin.
Stubbs RJ; Harker AJ
J Chromatogr B Biomed Appl; 1995 Aug; 670(2):279-85. PubMed ID: 8548018
[TBL] [Abstract][Full Text] [Related]
3. Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching.
Morris DM; Hussey BK; Geurin SL; Selinger KA
J Pharm Biomed Anal; 1995 Dec; 14(1-2):191-201. PubMed ID: 8833982
[TBL] [Abstract][Full Text] [Related]
4. Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry.
Baughman TM; Wright WL; Hutton KA
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):505-11. PubMed ID: 17324643
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
[TBL] [Abstract][Full Text] [Related]
7. Aqueous normal phase liquid chromatography coupled with tandem time-of-flight quadrupole mass spectrometry for determination of zanamivir in human serum.
Ge J; Liu F; Holmes EH; Ostrander GK; Li QX
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 906():58-62. PubMed ID: 22947416
[TBL] [Abstract][Full Text] [Related]
8. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
Matsumoto K; Ogawa N; Nerome K; Numazaki Y; Kawakami Y; Shirato K; Arakawa M; Kudoh S; Shimokata K; Nakajima S; Yamakido M; Kashiwagi S; Nagatake T
Antivir Ther; 1999; 4(2):61-8. PubMed ID: 10682150
[TBL] [Abstract][Full Text] [Related]
10. Determination of scopolamine in human serum and microdialysis samples by liquid chromatography-tandem mass spectrometry.
Oertel R; Richter K; Ebert U; Kirch W
J Chromatogr B Biomed Sci Appl; 2001 Jan; 750(1):121-8. PubMed ID: 11204211
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitors for preventing and treating influenza in children.
Matheson NJ; Symmonds-Abrahams M; Sheikh A; Shepperd S; Harnden A
Cochrane Database Syst Rev; 2003; (3):CD002744. PubMed ID: 12917931
[TBL] [Abstract][Full Text] [Related]
12. Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy.
Altschuler EL; Bhatia A; Kast RE
Kidney Int; 2005 Dec; 68(6):2910-1. PubMed ID: 16316376
[No Abstract] [Full Text] [Related]
13. Selective and sensitive liquid chromatography-tandem mass spectrometry method for the determination of levonorgestrel in human plasma.
Theron HB; Coetzee C; Sutherland FC; Wiesner JL; Swart KJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):331-6. PubMed ID: 15556549
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitors: zanamivir and oseltamivir.
McNicholl IR; McNicholl JJ
Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
16. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI; Barclay WS; Zambon MC
J Antimicrob Chemother; 2004 May; 53(5):759-65. PubMed ID: 15028666
[TBL] [Abstract][Full Text] [Related]
17. Treating influenza with zanamivir.
Read RC
Lancet; 1998 Dec; 352(9144):1872-3. PubMed ID: 9863779
[No Abstract] [Full Text] [Related]
18. New approaches to influenza chemotherapy. Neuraminidase inhibitors.
Calfee DP; Hayden FG
Drugs; 1998 Oct; 56(4):537-53. PubMed ID: 9806102
[TBL] [Abstract][Full Text] [Related]
19. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
[TBL] [Abstract][Full Text] [Related]
20. Does the availability of a neuraminidase inhibitor impair influenza vaccination? A report from Austria.
Kunze U; Groman E; Vymazal K; Hartl HK
Vaccine; 2001 Feb; 19(15-16):1854. PubMed ID: 11345055
[No Abstract] [Full Text] [Related]
[Next] [New Search]
